Justin D. Clubb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justin D. Clubb has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Torahito A. Gao
University of California, Los Angeles 1 Department of Chemical and Biomolecular Engineering Los Angeles, California
26 shared publications - Yvonne Y. Chen
Molecular Biology Institute, University of California, Los Angeles, Los Angeles, USA
26 shared publications - Amber Bouren
University of California, Los Angeles 3 Department of Microbiology, Immunology, and Molecular Genetics Los Angeles, California
25 shared publications - Han-Chung Wu
Institute of Cellular and Organismic Biology Academia Sinica Taipei Taiwan
25 shared publications - Ryan M. Shih
Molecular Biology Institute, University of California, Los Angeles, Los Angeles, USA
25 shared publications - Amanda Shafer
University of California, Los Angeles 3 Department of Microbiology, Immunology, and Molecular Genetics Los Angeles, California
24 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S13. H&E staining of mouse brains 7 days after ATC.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S13. H&E staining of mouse brains 7 days after ATC.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S14. Treatment with CAR-12.DR18 T cells does not lead to permanent brain tissue damage.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S14. Treatment with CAR-12.DR18 T cells does not lead to permanent brain tissue damage.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S19. FluoroSpot plate images of CD90.2+ cells isolated on ACT+2 and co-cultured with antigen-negative tumor cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S19. FluoroSpot plate images of CD90.2+ cells isolated on ACT+2 and co-cultured with antigen-negative tumor cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Table S1. Armors chosen for screening based on potential for macrophage reprogramming.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Table S1. Armors chosen for screening based on potential for macrophage reprogramming.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S7. ScRNAseq reveals CAR-12.18 induces IL18BP expression in brain myeloid cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S7. ScRNAseq reveals CAR-12.18 induces IL18BP expression in brain myeloid cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S2. In vivo screening of triple-armored CAR-T cells identify IL-12/DR-18/anti–IL-10 as a highly potent combination.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S2. In vivo screening of triple-armored CAR-T cells identify IL-12/DR-18/anti–IL-10 as a highly potent combination.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S15. Immunofluorescent images of CT-2A–bearing mouse brains after CAR-T cell treatment and intracardial dextran injection.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S15. Immunofluorescent images of CT-2A–bearing mouse brains after CAR-T cell treatment and intracardial dextran injection.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S10. Immunofluorescent images of healthy brain-tissue vasculature.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S10. Immunofluorescent images of healthy brain-tissue vasculature.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S5. CAR-12.18 is efficacious and non-toxic against SB28-GKO orthotopic syngeneic glioma.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S5. CAR-12.18 is efficacious and non-toxic against SB28-GKO orthotopic syngeneic glioma.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S3. Schematics of multi-cistronic armored CAR-T cell constructs.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma
Fig. S3. Schematics of multi-cistronic armored CAR-T cell constructs.